IASLC Lung Cancer Considered: ADCs in EGFR Mutant NSCLC
Update: 2025-12-02
Description
In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with Prof. Li Zhang and Dr. Elaine Shum about recent progress in antibody–drug conjugates (ADCs) for EGFR-mutant non-small cell lung cancer (NSCLC). They discuss new approvals of datopotamab deruxtecan (in the United States) and sacituzumab tirumotecan (in China), key findings from the TROPION and OptiTROP trials, and emerging agents. The conversation highlights the advances in efficacy, safety, and combination strategies that are shaping the evolving treatment landscape for patients with EGFR-mutant NSCLC.
Guest: Li Zhang, MD
Professor, Medical Oncology Department
Sun Yat-Sen University Cancer Center
No Social
Guest: Elaine Shum, MD
Assistant Professor
Director of Cancer Screening Programs
New York University Perlmutter Cancer Center
Guest: Li Zhang, MD
Professor, Medical Oncology Department
Sun Yat-Sen University Cancer Center
No Social
Guest: Elaine Shum, MD
Assistant Professor
Director of Cancer Screening Programs
New York University Perlmutter Cancer Center
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
